News | MBX Biosciences

Press Releases

2022 2021 2020 2019

MBX Biosciences to Participate in Jefferies Healthcare Conference

May 22, 2023/in news, PR/by Ellie Solorio

May 24, 2023

MBX Biosciences to Participate in May Investor Conferences

May 3, 2023/in news, PR/by Ellie Solorio

May 8, 2023

MBX Biosciences to Participate in the Needham 22nd Annual Healthcare Conference

April 6, 2023/in news, PR/by Ellie Solorio

April 10, 2023

MBX Biosciences to Participate in the Oppenheimer 33rd Annual Healthcare Conference

March 7, 2023/in news, PR/by David Anderson

March 7, 2023

MBX Biosciences to Participate in the SVB Securities Global Biopharma Conference

January 23, 2023/in news, PR/by David Anderson

January 24, 2023

MBX Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 4, 2023/in news, PR/by David Anderson

January 5, 2023

MBX Biosciences Closes $115 Million Series B Financing to Advance Development of Endocrine Disease Programs

November 10, 2022/in news, PR/by Ellie Solorio

November 14, 2022

MBX Biosciences Advances Phase 1 Clinical Trial of Long-Acting Parathyroid Hormone Peptide Prodrug, MBX 2109

October 5, 2022/in news, PR/by David Anderson

October 5, 2022

MBX Biosciences Receives Orphan Drug Designation for Lead Candidate MBX 2109

July 26, 2022/in news, PR/by Tim

July 26, 2022

MBX Biosciences Appoints Richard B. Bartram As Chief Financial Officer

April 13, 2022/in news, PR/by eallison

April 11, 2022

MBX Biosciences Appoints Ora Hirsch Pescovitz, M.D. To Board Of Directors

April 13, 2022/in news, PR/by eallison

April 5, 2022

MBX Biosciences Appoints Mary Jane Geiger, M.D., Ph.D., as Chief Medical Officer

February 7, 2022/in news, PR/by Emily Hennes

January 5, 2021

MBX Biosciences Announces Board Appointment of Industry Veteran

February 7, 2022/in PR/by Emily Hennes

October 27, 2020

MBX Biosciences Closes $34.6 Million Series A Financing in Rare Endocrine Diseases

February 7, 2022/in PR/by Emily Hennes

July 27, 2020

MBX Biosciences Announces Closing of Seed Funding

February 7, 2022/in PR/by Emily Hennes

September 10, 2019

Blog

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore

February 7, 2022/in Blog/by Emily Hennes

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore

February 7, 2022/in Blog/by Emily Hennes

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore

February 7, 2022/in Blog/by Emily Hennes

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore

February 7, 2022/in Blog/by Emily Hennes

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore

February 7, 2022/in Blog/by Emily Hennes

Media and Investor Contacts

Media Contact

Ian Stone

Canale Communications

Ian.stone@canalecomm.com

619-849-5388

Investor Relations Contact

Irina Koffler

LifeSci Advisors

ikoffler@lifesciadvisors.com

917-734-7387